Media releases - Roche
WEBStay updated. Get the latest news and updates to your inbox. This website contains information on products which is targeted to a wide range of audiences and could contain product details or information otherwise not accessible or valid in your country.
FDA approves Roche’s Ocrevus Zunovo with Halozyme Enhanze
WEBR oche has secured approval from the US Food and Drug Administration (FDA) for Ocrevus Zunovo (ocrelizumab and hyaluronidase-ocsq) with biopharmaceutical company Halozyme Therapeutics's Enhanze...
Roche closes acquisition of LumiraDx’s Point of Care technology …
WEBJul 29, 2024 · Roche announced the signing of its agreement to acquire LumiraDx’s Point of Care technology at the end of 2023. Continued Partnership with the Bill & Melinda Gates Foundation.
Roche Stock Down on Concerns of Side-Effects From Its Obesity …
WEBSep 12, 2024 · In the latest presentation, Roche stated that the headline result of 6.1% weight loss over four weeks was based on the treatment of just six patients. Hence, this also raises concerns of efficacy.
How Roche passed on a potential $14bn-a-year weight-loss pill
WEBAug 15, 2024 · Swiss drugmaker Roche turned down a potential $14bn-a-year weight-loss pill now being developed by rival Eli Lilly that could have given it a leading position in the booming weight-loss...
Roche Shares Drop on Concern About Obesity Pill Side Effects
WEBSep 11, 2024 · (Bloomberg) -- Roche Holding AG’s shares slid the most in more than a month after its closely-watched experimental obesity pill was tied to side effects, raising questions about the drugmaker ...
Roche touts early trial success of second obesity drug candidate
WEBJuly 17 (Reuters) - Roche (ROG.S) said on Wednesday a second drug candidate from its purchase of Carmot Therapeutics yielded positive results in an early-stage trial, as the Swiss drugmaker...
Roche to accelerate Wegovy weight loss rivals after positive trials
WEBJul 29, 2024 · Swiss pharmaceutical giant Roche said Monday it is accelerating the development of its Wegovy rival weight loss drugs following promising early stage trial data. The company’s two obesity drug...
FDA approves Roche’s Alecensa as the first adjuvant
WEBBasel, 19 April 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has approved Alecensa® (alectinib) for adjuvant treatment following...
Roche granted FDA Breakthrough Device Designation for pTau217 …
WEBRoche announced today that its Elecsys pTau217 assay received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA).